Tubulis completed a large late-stage private financing to accelerate clinical programs for next-generation antibody-drug conjugates (ADCs). The Munich-based biotech secured roughly $360–361 million in a Series C round that investors say will fund expansion of its lead ADC, TUB-040, into earlier lines and additional tumor types and support its broader pipeline. The company plans to present first clinical data at a major European oncology meeting; Tubulis is testing TUB-040 in ovarian cancer and non–small cell lung cancer. Coverage: STAT and multiple trade reports confirmed the round and described investor participation and intended use of funds. The financing positions Tubulis to push ADC optimization and broaden clinical development where payload and linker chemistry matter for safety and efficacy. Technical note: ADCs are targeted therapies that link an antibody to a cytotoxic payload to concentrate cell-killing activity at tumor cells while sparing normal tissue. Tubulis’ raise is notable for its size at the private-stage ADC market and signals investor appetite for differentiated conjugate platforms.